PRESS RELEASE
Quatre Lab Enters the US Market in Partnership with Elpida Therapeutics as a Key Ally in Advanced Therapy Validation
- Quatre Lab embarks on its journey in the North American market by collaborating with Elpida Tx, an innovative company dedicated to developing therapeutic solutions for rare diseases.
- The Spanish company specialises in quality control and potency verification of advanced pharmaceutical therapies.
Los Ángeles (USA), Gipuzkoa (Spain) – 6 February 2025 – The Contract Research Organisation (CRO) Quatre Lab takes a significant step in its international expansion strategy by establishing a presence in the North American market. In this highly demanding market, Quatre Lab has partnered with Elpida Therapeutics (Elpida Tx) to verify the potency of its products. This marks a milestone in Quatre Lab’s commitment to excellence in quality control for advanced therapies, further solidifying its reputation as a CRO industry leader.
Quatre Lab aims to establish itself as a reference in quality control and potency evaluation for advanced therapies in the North American market. Based at the Science and Technology Park of Gipuzkoa (Basque Country, Spain) —an innovation-driven hub—it is part of a vibrant ecosystem of biotech companies and global leaders in gene therapy. This strategic location enables Quatre Lab to leverage key synergies and remain at the forefront of this highly specialised field. Under the leadership of Ph.D. Patricia Muñoz, a Biomedical Research expert, Quatre Lab delivers flexible solutions tailored to the stringent international standards of regulatory agencies such as the FDA, ensuring the quality and safety of advanced therapies reaching patients.
In its debut project in North America, Quatre Lab has collaborated with Elpida Tx, a pioneering organisation founded by Terry Pirovolakis to develop innovative treatments for rare diseases such as SPG50, a devastating hereditary condition. This collaboration allowed Elpida to validate the potency of commercialized produced product, reaffirming Quatre Lab’s capacity to uphold the highest quality standards in pharmaceutical therapies.
“Our goal is to transform the North American market by demonstrating that excellence in quality control, especially in potency testing, is essential to ensuring the safety and efficacy of advanced therapies. We are proud to collaborate with Elpida Tx, providing critical solutions in an essential area of their products for clinical and regulatory success and contributing to their inspiring fight to improve patients’ lives,” said Patricia Muñoz, CEO of Quatre Lab.
Terry Pirovolakis, CEO of Elpida, also expressed his enthusiasm for the partnership: “Quatre Lab’s work has been instrumental in evaluating the quality of our treatments. Their commitment to rigour and excellence has been pivotal in advancing our efforts towards effective solutions aimed at improving the lives of patients with rare diseases like SPG50, and their families. We extend our gratitude to the entire team for their dedication and hard work in supporting our Phase III program and successfully not just meeting but exceeding our requirements.
This alliance reinforces Quatre Lab’s commitment to translating cutting-edge research into safe and effective treatments and positions the company as a frontrunner in advanced therapy quality control. Furthermore, this strategic move underlines the shared mission of both companies to propel biotech innovation and lead the transformation of the global healthcare sector.
About Quatre Lab
Quatre Lab is a Contract Research Organization (CRO) based in San Sebastián, Spain, specializing in quality control testing for Advanced Therapy Medicinal Products (ATMPs). Quatre Lab supports pharmaceutical and biotech companies from preclinical stages to commercialization with GMP-compliant analytical services, ensuring the safety and efficacy of innovative therapies.
For more information: https://www.quatrelab.com
About Elpida Tx
Elpida Therapeutics is dedicated to delivering life-saving therapies for ultra-rare diseases. Founded to tackle the unmet medical needs of children living with rare conditions, Elpida works to rapidly advance its therapeutic programs in partnership with leading researchers and institutions around the globe.
For more information: www.elpidatx.com
Media contacts
- Terry Pirovolakis – CEO & Founder Elpida Tx 4166251933 info@elpidatx.com
- Patricia Muñoz – CEO Quatre Lab (+34)943062666 pmunoz@quatrelab.com
